Larry Ereshefsky

7.4k total citations
129 papers, 4.7k citations indexed

About

Larry Ereshefsky is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Larry Ereshefsky has authored 129 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Psychiatry and Mental health, 47 papers in Pharmacology and 21 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Larry Ereshefsky's work include Schizophrenia research and treatment (37 papers), Treatment of Major Depression (34 papers) and Bipolar Disorder and Treatment (19 papers). Larry Ereshefsky is often cited by papers focused on Schizophrenia research and treatment (37 papers), Treatment of Major Depression (34 papers) and Bipolar Disorder and Treatment (19 papers). Larry Ereshefsky collaborates with scholars based in United States, United Kingdom and France. Larry Ereshefsky's co-authors include Y. W. Francis Lam, Stephen R. Saklad, Michael W. Jann, Alexander L. Miller, Cara L. Alfaro, Chester M. Davis, David C. Glahn, Natalie Maples, Ann L. Richards and William M. Glazer and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Larry Ereshefsky

126 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larry Ereshefsky United States 42 2.4k 1.1k 749 580 500 129 4.7k
Michael W. Jann United States 39 2.1k 0.9× 1.1k 1.0× 734 1.0× 748 1.3× 349 0.7× 133 5.1k
Paul J. Perry United States 44 2.3k 1.0× 1.0k 0.9× 267 0.4× 355 0.6× 699 1.4× 155 6.0k
Del D. Miller United States 52 5.0k 2.1× 852 0.8× 350 0.5× 394 0.7× 861 1.7× 135 8.4k
B. Müller‐Oerlinghausen Germany 42 4.1k 1.7× 1.2k 1.0× 372 0.5× 804 1.4× 1.3k 2.6× 262 6.5k
Olav Spigset Norway 47 2.3k 1.0× 1.1k 1.0× 831 1.1× 1.7k 3.0× 657 1.3× 366 8.4k
Franca Centorrino United States 30 3.6k 1.5× 770 0.7× 151 0.2× 385 0.7× 703 1.4× 58 4.6k
Prakash S. Masand United States 42 2.5k 1.0× 1.6k 1.4× 156 0.2× 310 0.5× 690 1.4× 225 5.5k
Sheldon Preskorn United States 48 3.0k 1.2× 3.4k 3.1× 1.1k 1.5× 729 1.3× 677 1.4× 324 8.2k
Pierre Baumann Switzerland 53 2.7k 1.1× 2.2k 2.0× 2.1k 2.8× 1.4k 2.5× 365 0.7× 322 8.7k
Bernard Bégaud France 34 1.3k 0.5× 1.1k 1.0× 344 0.5× 448 0.8× 218 0.4× 179 6.8k

Countries citing papers authored by Larry Ereshefsky

Since Specialization
Citations

This map shows the geographic impact of Larry Ereshefsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Ereshefsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Ereshefsky more than expected).

Fields of papers citing papers by Larry Ereshefsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Ereshefsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Ereshefsky. The network helps show where Larry Ereshefsky may publish in the future.

Co-authorship network of co-authors of Larry Ereshefsky

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Ereshefsky. A scholar is included among the top collaborators of Larry Ereshefsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Ereshefsky. Larry Ereshefsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, David S., Daniel R. Bateman, Jeffrey L. Cummings, et al.. (2025). Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders. International Psychogeriatrics. 37(5). 100074–100074.
2.
Atsou, Kokuvi, Larry Ereshefsky, Mélanie Brignone, et al.. (2020). Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research. 21(1). 29–42. 2 indexed citations
3.
Cebers, Gvido, Robert Alexander, Samantha Budd Haeberlein, et al.. (2016). AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease. Journal of Alzheimer s Disease. 55(3). 1039–1053. 68 indexed citations
4.
Fava, Maurizio, Karl Johe, Larry Ereshefsky, et al.. (2015). A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Molecular Psychiatry. 21(10). 1372–1380. 38 indexed citations
5.
Ereshefsky, Larry, et al.. (2014). Lurasidone drug-drug interaction studies: a comprehensive review. Drug metabolism and drug interactions. 29(3). 191–202. 29 indexed citations
6.
Katz, David A., C. Locke, Peer B. Jacobson, et al.. (2013). Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Translational Psychiatry. 3(8). e295–e295. 12 indexed citations
7.
Bursi, Roberta, Peter Dogterom, Larry Ereshefsky, et al.. (2012). Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients. Drugs in R&D. 12(3). 127–139. 17 indexed citations
8.
Ereshefsky, Larry, Delphine Saragoussi, Nicolas Despiégel, et al.. (2010). The 6-month persistence on SSRIs and associated economic burden. Journal of Medical Economics. 13(3). 527–536. 22 indexed citations
9.
Lam, Y. W. Francis, Larry Ereshefsky, Andreas Port, C. J. Timmer, & Peter Dogterom. (2009). Effects of Rifampin on the Disposition of Gepirone ER and Its Metabolites. 3. 1–7. 3 indexed citations
10.
Zhang, Lu, Jill Chappell, Celedon Gonzales, et al.. (2007). QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study. Journal of Cardiovascular Pharmacology. 49(3). 146–153. 52 indexed citations
11.
Lefèvre, Gilbert, G Sędek, S. S. Jhee, et al.. (2007). Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients. Clinical Pharmacology & Therapeutics. 83(1). 106–114. 106 indexed citations
12.
Velligan, Dawn I., Mei Wang, Pamela M. Diamond, et al.. (2007). Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications. Psychiatric Services. 58(9). 1187–1192. 182 indexed citations
13.
Jhee, S. S., Amy S. Chappell, Victoria Zarotsky, et al.. (2006). Multiple‐Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects. The Journal of Clinical Pharmacology. 46(4). 424–432. 26 indexed citations
14.
Glahn, David C., et al.. (2005). Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature. Schizophrenia Bulletin. 32(4). 724–742. 233 indexed citations
15.
Ereshefsky, Larry. (2001). The Texas Medication Algorithm Project for major depression.. PubMed. 10(8 Suppl). 16–7; discussion 18. 2 indexed citations
16.
Ereshefsky, Larry, et al.. (1993). Neuroleptic Malignant Syndrome Associated With Clozapine Monotherapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 13(5). 510–514. 25 indexed citations
17.
Ereshefsky, Larry, et al.. (1993). A Loading-Dose Strategy for Converting From Oral to Depot Haloperidol. Psychiatric Services. 44(12). 1155–1161. 14 indexed citations
18.
Ereshefsky, Larry, Chester M. Davis, Charles A. Harrington, et al.. (1984). Haloperidol and Reduced Haloperidol Plasma Levels in Selected Schizophrenic Patients. Journal of Clinical Psychopharmacology. 4(3). 138???142–138???142. 57 indexed citations
19.
Ereshefsky, Larry, et al.. (1983). Management of chronic, refractory schizophrenic patients with high-dose loxapine. 19(4). 600–603. 1 indexed citations
20.
Ereshefsky, Larry, et al.. (1979). Treatment of tardive dyskinesia and mania with RBC lithium determinations.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 136(4B). 570–3. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael W. Jann Breakdown of academic impact, for papers by Paul J. Perry Breakdown of academic impact, for papers by Del D. Miller Breakdown of academic impact, for papers by B. Müller‐Oerlinghausen Breakdown of academic impact, for papers by Olav Spigset Breakdown of academic impact, for papers by Franca Centorrino Breakdown of academic impact, for papers by Prakash S. Masand Breakdown of academic impact, for papers by Sheldon Preskorn Breakdown of academic impact, for papers by Pierre Baumann Breakdown of academic impact, for papers by Bernard Bégaud
Rankless by CCL
2026